You are here

Our science / Clinical Trials / Find a Trial / NCT00770289

Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)

Back to Search Print Save as PDF Bookmark Trial

NCT00770289

Last updated on May 11, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Haidari, Athens, 12461 Greece
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Major Depressive Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Outpatients

- 18-75 years old

- Patients diagnosed with MDD according to DSM IV without psychotic symptoms

- HAM-D17 > or = 18 on inclusion

- Patients receiving treatment for the first time or changing treatment based on their
doctor's decision

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects with potentially problematic compliance

- Subjects participating in an interventional trial within the last 3 months

NCT00770289
Pfizer
Completed
Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Sickle Cell Anemia, Sickle Cell Disease, Sickle Cell Disorders, Pain Crisis, Vaso-occlusive Crisis
Safety Of Rivipansel (GMI-1070) In The Treatment Of One or More Vaso-occlusive Crises In Hospitalized Subjects With Sickle Cell Disease
NCT02433158
All Genders
6+
Years
Multiple Sites
Attention Deficit Hyperactivity Disorder (ADHD)
6 Month OL Study to Evaluate the Safety, Tolerability and Efficacy of Methylphenidate HCl ERCT in Children With ADHD.
NCT03580005
All Genders
Obsessive Compulsive Disorder
Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)
NCT01302080
All Genders
6+
Years
Multiple Sites
Bipolar Disorder
Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder
NCT02075047
All Genders
10+
Years
Multiple Sites
Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)
Open Label, Observational, Non-interventional Study for the Evaluation of Remission Rates in Patients With MDD Under Treatment With Various Anti-depressives
Tools known as 'depression scales 'are widely used as assessments to evaluate a patient's response to treatment. The purpose of this study is the evaluation of the remission rates for patients with MDD. The evaluation will involve the use of HAM-D 17, and HAM-D 7 questionnaires and the comparison of those questionnaires.
12 weeks random
Observational
Observational Model: Cohort
Not Provided
Not Provided
Probability Sample
Patients diagnosed with MDD who are either changing treatment or have never received treatment.
Major Depressive Disorder
Other: Cohort
Cohort (Patients diagnosed with MDD who are either changing treatment or have never received treatment).
Single group
Intervention: Other: Cohort
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
851
December 2009
December 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Outpatients
  • 18-75 years old
  • Patients diagnosed with MDD according to DSM IV without psychotic symptoms
  • HAM-D17 > or = 18 on inclusion
  • Patients receiving treatment for the first time or changing treatment based on their doctor's decision

Exclusion Criteria:

  • Subjects with potentially problematic compliance
  • Subjects participating in an interventional trial within the last 3 months
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Greece
 
 
NCT00770289
0600B-102374
B2411003 ( Other Identifier: Pfizer )
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
August 2012

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now